Skip to main content

Media Category: Safety, Tolerability & Adherence

Real-Life Experiences with biosimilars 

Written by ParadigMS Foundation on .

Key takeaways Generics and biosimilars are increasingly relevant in Multiple Sclerosis (MS) as healthcare systems seek cost containment without compromising clinical outcomes. Biosimilars are not identical copies, but are rigorously evaluated to demonstrate high similarity to reference biologics in structure, efficacy, safety, and immunogenicity through the EMA/FDA “totality of evidence” framework. Clinical trials and real-world evidence consistently show comparable efficacy and safety between originator biologics and biosimilars used in MS, including interferon beta, rituximab (off-label),...

Continue reading

Real Life Experiences with Biosimilars

Written by ParadigMS Foundation on .

This expert-led webinar explored real-world experience with biosimilars in the treatment of Multiple Sclerosis (MS), with a particular focus on biosimilar natalizumab. Organized by ParadigMS, the session brought together Jelena Drulovic and Tjalf Ziemssen to discuss regulatory principles, clinical evidence, and practical challenges encountered in daily neurological practice. Professors reviewed the scientific and regulatory framework for biosimilars, emphasizing the concept of “totality of evidence” required for approval, including analytical, functional, pharmacokinetic, pharmacodynamic,...

Continue reading

Astrocytes and myelin – Clinical aspects: available and future treatment

Written by ParadigMS Foundation on .

This lecture explains how antibody-mediated pathology translates into clinical phenotypes and treatment strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Melinda Magyari contrasts the core targets, astrocytes (aquaporin-4) in NMOSD versus myelin/oligodendrocytes (MOG) in MOGAD, and shows how these mechanisms drive differences in relapse recovery, long-term disability, and therapeutic priorities. A major emphasis is placed on early antibody testing to avoid misdiagnosis (particularly as Multiple Sclerosis) and...

Continue reading

Sphingosine system – Clinical aspects: available and future treatment

Written by ParadigMS Foundation on .

This lecture reviews the clinical use of sphingosine-1-phosphate (S1P) receptor modulators in Multiple Sclerosis, with a focus on their mechanisms of action, receptor selectivity, pharmacokinetics, and safety considerations. Magd Zakaria discusses how differences in half-life, metabolism, and receptor targeting influence efficacy, adverse events, monitoring requirements, and treatment sequencing, including switching strategies and special populations such as women planning pregnancy. Key Insights from the Lecture: S1P receptor modulators exert their therapeutic effect by modulating...

Continue reading

Immune reconstitution–pathology and pathway

Written by ParadigMS Foundation on .

In this keynote from Athens presented by Bart Van Wijmeersch, the concept of immune reconstitution therapy (IRT) in multiple sclerosis is examined from a mechanistic and clinical perspective. The presentation focuses on how targeted depletion and controlled repopulation of immune cells may rebalance dysregulated immunity, enhance tolerance, and reshape long-term disease activity. Key Insights from the Lecture: Immune reconstitution as a goal: restoring immune balance and tolerance is presented as a core objective in MS, by resetting dysregulated regulatory and effector cells. The...

Continue reading

B-Cell Clinical aspects: available and future treatment

Written by ParadigMS Foundation on .

In this keynote delivered in Athens, Professor Carlo Pozzilli takes the audience through the past, present and future of anti-CD20 therapies in multiple sclerosis. Starting from the early interferon era and the first monoclonal antibodies, Professor Pozzilli retraces how B-cell depletion moved from a provocative concept to a central pillar of MS management. Drawing on pivotal trials, 10-year extension data and real-world evidence, the discussion adresses why starting high-efficacy therapy early matters, how anti-CD20 agents compare with other high-efficacy options such as natalizumab, and...

Continue reading

  • 1
  • 2

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.